These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 38171343)
1. Mechanistic Links between Central Obesity and Cardiorenal Metabolic Diseases. Al-Chalabi S; Syed AA; Kalra PA; Sinha S Cardiorenal Med; 2024; 14(1):12-22. PubMed ID: 38171343 [TBL] [Abstract][Full Text] [Related]
2. Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Aroor AR; McKarns S; Demarco VG; Jia G; Sowers JR Metabolism; 2013 Nov; 62(11):1543-52. PubMed ID: 23932846 [TBL] [Abstract][Full Text] [Related]
3. Range of adiposity and cardiorenal syndrome. Pazos F World J Diabetes; 2020 Aug; 11(8):322-350. PubMed ID: 32864046 [TBL] [Abstract][Full Text] [Related]
4. Obesity, kidney dysfunction, and inflammation: interactions in hypertension. Hall JE; Mouton AJ; da Silva AA; Omoto ACM; Wang Z; Li X; do Carmo JM Cardiovasc Res; 2021 Jul; 117(8):1859-1876. PubMed ID: 33258945 [TBL] [Abstract][Full Text] [Related]
5. Obesity Treatments to Improve Type 1 Diabetes (OTID): a randomized controlled trial of the combination of glucagon-like peptide 1 analogues and sodium-glucose cotransporter 2 inhibitors-protocol for Obesity Treatments to Improve Type 1 Diabetes (the OTID trial). Al-Ozairi E; Narula K; Miras AD; Taghadom E; Samad AE; Al Kandari J; Alyosef A; Mashankar A; Al-Najim W; le Roux CW Trials; 2024 Feb; 25(1):129. PubMed ID: 38365744 [TBL] [Abstract][Full Text] [Related]
6. The Renin Angiotensin Aldosterone System in Obesity and Hypertension: Roles in the Cardiorenal Metabolic Syndrome. Cabandugama PK; Gardner MJ; Sowers JR Med Clin North Am; 2017 Jan; 101(1):129-137. PubMed ID: 27884224 [TBL] [Abstract][Full Text] [Related]
8. Mortality and Renal Outcomes Are Impacted by Obesity in Cardiorenal Metabolic Disease but Not in People with Concomitant Diabetes Mellitus. Al-Chalabi S; Chinnadurai R; Kalra PA; Sinha S Cardiorenal Med; 2024; 14(1):23-33. PubMed ID: 38160668 [TBL] [Abstract][Full Text] [Related]
9. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Hall JE; do Carmo JM; da Silva AA; Wang Z; Hall ME Circ Res; 2015 Mar; 116(6):991-1006. PubMed ID: 25767285 [TBL] [Abstract][Full Text] [Related]
10. RAAS inhibition and cardiorenal syndrome. Onuigbo MA Curr Hypertens Rev; 2014; 10(2):107-11. PubMed ID: 25549841 [TBL] [Abstract][Full Text] [Related]
11. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis. Yang S; Zhao L; Mi Y; He W Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807 [TBL] [Abstract][Full Text] [Related]
12. Association of metabolic syndrome and chronic kidney disease. Scurt FG; Ganz MJ; Herzog C; Bose K; Mertens PR; Chatzikyrkou C Obes Rev; 2024 Jan; 25(1):e13649. PubMed ID: 37783465 [TBL] [Abstract][Full Text] [Related]
13. Obesity, kidney dysfunction and hypertension: mechanistic links. Hall JE; do Carmo JM; da Silva AA; Wang Z; Hall ME Nat Rev Nephrol; 2019 Jun; 15(6):367-385. PubMed ID: 31015582 [TBL] [Abstract][Full Text] [Related]
14. SGLT2i for evidence-based cardiorenal protection in diabetic and non-diabetic chronic kidney disease: a comprehensive review by EURECA-m and ERBP working groups of ERA. Mark PB; Sarafidis P; Ekart R; Ferro CJ; Balafa O; Fernandez-Fernandez B; Herrington WG; Rossignol P; Del Vecchio L; Valdivielso JM; Mallamaci F; Ortiz A; Nistor I; Cozzolino M Nephrol Dial Transplant; 2023 Oct; 38(11):2444-2455. PubMed ID: 37230946 [TBL] [Abstract][Full Text] [Related]